Page 3 - Scientific Session News Today

Drinking more than eight alcoholic drinks a week put women 50% more at risk to develop the potentially fatal condition.

A REDUCE-IT analysis highlights consistent cardiovascular benefits with icosapent ethyl across varying levels of Lp(a).

Bristol Myers Squibb has announced that it will present data on CAMZYOS (mavacamten) for NYHA class II-III obstructive hypertrophic cardiomyopathy at the American College of Cardiology (ACC) Annual Scientific Session & Expo, ACC.24, taking place April 6-8, 2024 in Atlanta, Georgia.

Here is a look at the education and special events planned for the ACC24 73rd Annual Scientific Session & Expo, April 6-8 in Atlanta

REYNOLDSVILLE — Reynoldsville man William Cebulskie, a current graduate student studying medical science, recently received national recognition for his pediatric cardiac arrest research.

Stanford University Professor of Radiology, Medicine and Biomedical Data Science; Director of the Center for Artificial Intelligence in Medicine and  Imaging (AIMI Center); Associate Director of Stanford’s Institute for Human-Centered Artificial Intelligence (HAI); and Associate Chair for Information Systems, Medical Informatics Director for Stanford Health Care  

This year’s top 5 most-read articles on pulmonary arterial hypertension (PAH) explored expert opinions on treatment approaches, data on newly emerging therapies, the impacts of alcohol, and more.

Our top coverage from the 72nd American College of Cardiology (ACC) Scientific Session included results from the STELLAR, CLEAR Outcomes, ACCESS, and HALO trials.

Paul Ridker, MD, MPH, discusses the evolving recognition of the role inflammation plays in driving cardiovascular risk among patients with atherosclerosis.

Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, including minimal symptom expression in generalized myasthenia...